Vilon is described as a synthetic Lys-Glu dipeptide connected with the short peptide bioregulator work of Vladimir Khavinson's group in Russia. The supplied evidence frames interest around immune function, thymic biology, and longevity, but it also says the evidence is mainly animal work and lacks registered Western randomized human trials.

The proposed model is gene regulation rather than a well-validated receptor target. The source describes a hypothesis in which very short peptides may enter cells, interact with nuclear biology, and influence immune-related or DNA-repair gene expression and chromatin behavior in lymphocyte experiments. This remains a research model, not an established drug mechanism.

Is Vilon FDA approved?

No. The supplied source lists Vilon as not FDA approved and describes its status as available in Russia.

What are the side effects of Vilon?

The source lists generally good tolerability, brief injection-site discomfort, a mouse-model breast-cancer caution, and limited human safety data. It also contains tumor-related statements that need review because cited mouse findings are described elsewhere as tumor-inhibitory.

What is the typical dose of Vilon?

The source reports a community dose of 10-20 mg daily, once or twice daily, with oral capsules or sublingual administration and 10-30 day courses. This is reported-source dosing only and should not be treated as medical guidance.

Bioregulators Preclinical - animal studies only

Vilon

Also known as: Lys-Glu, KE Dipeptide

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Preclinical Lys-Glu bioregulator studied for immune and thymic aging questions

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral capsules or sublingual

Researched for

Immune enhancement, thymic function, longevity

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Synthetic Lys-Glu dipeptide also called KE Dipeptide.
Categorized by the source as a thymus-associated bioregulator.
Evidence is described as animal-study based, with no registered Western randomized human trials in the supplied material.
Reported dosing in the source is 10-20 mg daily, once or twice daily, by oral capsule or sublingual route.
Research interest is listed for immune enhancement, thymic function, and longevity.

How it's thought to work

Vilon is presented as a short Lys-Glu dipeptide with a proposed bioregulatory mechanism. The source links it to hypotheses about cellular entry, nuclear effects, immune-related gene expression, DNA-repair gene expression, and chromatin changes seen in cultured lymphocytes. Those points are described as tentative; the supplied evidence does not establish precise molecular targets or independent validation comparable to an approved medicine.

What the research shows

Where the research stands

The source characterizes Vilon research as narrow and largely . It describes mouse work from Khavinson, Anisimov, and colleagues around 2000, including studies in female CBA mice that reported changes such as increased activity, small lifespan effects, and tumor-related outcomes. The same source stresses major limits: a single research lineage, modest reported effects, limited independent replication, and no registered Western randomized human trial evidence. Human anti-aging or immune-rejuvenation claims therefore remain extrapolations from early animal and laboratory findings.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Available in Russia - Not FDA approved Not FDA Approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported use describes Vilon as a Khavinson-style dipeptide bioregulator used in short cycles. This dosing information is not evidence of clinical efficacy or safety. · Oral or sublingual · 10-30 day cycles

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Research Literature - Observed in studies

Animal study doses may not translate directly to humans.

Duration: 10-30 day courses
Administration: Oral capsules or sublingual

Timing & administration

Best time to take

Morning

Once daily or as directed

Food recommendation

With or without food

Why this timing?

The source suggests morning use because immune activity is framed as more daytime-oriented, but this is a rationale statement rather than validated clinical timing evidence.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally reported as well tolerated
Brief injection-site discomfort
Breast-cancer caution in mouse models
Limited human safety data

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Lys-Glu-OH (KE)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Vilon

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Vilon

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions

What does Vilon do?

How does Vilon work?